Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abemaciclib + abiraterone acetate + prednisone
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A **combination therapy** consisting of abemaciclib (a selective cyclin-dependent kinase 4 and 6 inhibitor), abiraterone acetate (an inhibitor of androgen biosynthesis), and prednisone (a synthetic corticosteroid). This regimen is under investigation for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abemaciclib inhibits tumor cell proliferation by blocking CDK4/6-mediated cell cycle progression. Abiraterone acetate reduces androgen production by inhibiting CYP17A1, thereby decreasing androgen receptor (AR) activation—a key driver of prostate cancer growth. Prednisone is used to counteract mineralocorticoid excess and provide anti-inflammatory effects. The combination aims to maximize androgen receptor-directed therapy through multi-modal blockade of proliferation and hormonal resistance mechanisms[3][1][2][4][6].
- Other names
- abemaciclib + abiraterone acetate + prednisone
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on abemaciclib + abiraterone acetate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abemaciclib + abiraterone acetate + prednisone.